

Received
12-5-02

I hereby certify that this correspondence is being sent via Facsimile to
Examiner Davis at 703-872-9307 On December 5, 2002

By: [Signature]Attorney Docket No.: 020093-000120US PATENT 160
12-18-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gerald P. Murphy et al.

Application No.: 09/016,737

Filed: January 30, 1998

For: ISOLATION AND/OR
PRESERVATION OF DENDRITIC
CELLS FOR PROSTATE CANCER
IMMUNOTHERAPY

Examiner: Minh-Tam Davis

Art Unit: 1642

AMENDMENT REPLY/AFTER FINAL
REJECTIONAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Rejection mailed July 5, 2002, please amend the
above-identified application as follows:

IN THE CLAIMS:

Kindly replace claim 23 with the following substitute claim. An Appendix
showing all changes to the claim is attached to this amendment as required by 37 C.F.R.
§ 1.121(c).

23. (Five Times Amended) A composition comprising an isolated cell
population exposed *in vitro* to a soluble prostate antigen, the cell population having an
increased number of human dendritic cells competent and able to activate T cells specific
to a prostate antigen as compared to an isolated cell population, comprising the same
number of cells, that has not been exposed *in vitro* to the prostate antigen.

51
On
12/11